|標題：Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial|
|作品名稱||Sodium Benzoate, a D-amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial|
|著者||Chieh-Hsin Lin; Ching-Hua Lin; Yue-Cune Chang; Yu-Jhen Huang; Po-Wei Chen; Hsien-Yuan Lane|
|著錄名稱、卷期、頁數||Biological Psychiatry 84(6), p.422-432|
|摘要||BACKGROUND: Clozapine is the last-line antipsychotic agent for refractory schizophrenia. To date, there is no
convincing evidence for augmentation on clozapine. Activation of N-methyl-D-aspartate receptors, including
inhibition of D-amino acid oxidase that may metabolize D-amino acids, has been reported to be beneficial for
patients receiving antipsychotics other than clozapine. This study aimed to examine the efficacy and safety of a
D-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine.
METHODS: We conducted a randomized, double-blind, placebo-controlled trial. Sixty schizophrenia inpatients that
had been stabilized with clozapine were allocated into three groups for 6 weeks’ add-on treatment of 1 g/day sodium
benzoate, 2 g/day sodium benzoate, or placebo. The primary outcome measures were Positive and Negative
Syndrome Scale (PANSS) total score, Scale for the Assessment of Negative Symptoms, Quality of Life Scale, and
Global Assessment of Functioning. Side effects and cognitive functions were also measured.
RESULTS: Both doses of sodium benzoate produced better improvement than placebo in the Scale for the
Assessment of Negative Symptoms. The 2 g/day sodium benzoate also produced better improvement than placebo
in PANSS-total score, PANSS-positive score, and Quality of Life Scale. Sodium benzoate was well tolerated without
evident side effects. The changes of catalase, an antioxidant, were different among the three groups and correlated
with the improvement of PANSS-total score and PANSS-positive score in the sodium benzoate group.
CONCLUSIONS: Sodium benzoate adjuvant therapy improved symptomatology of patients with clozapine-resistant
schizophrenia. Further studies are warranted to elucidate the optimal
|關鍵字||Antioxidant;Clinical trial;D-amino acid oxidase (DAAO) inhibitor, N-methyl-D-aspartate;Refractory schizophrenia;Sodium benzoate|